Opening: Real consultation scenario
"Doctor, I've had three semen analyses and none showed sperm. Does that mean I can never have my own child?" Mr. Zhang, 32, laid three semen analysis reports flat on the consultation desk. The conclusion column of each read "No sperm found after centrifugation." His wife sat beside him, her eyes slightly reddened. This scene occurs almost daily in the reproductive andrology clinic. Azoospermia – a diagnosis that sounds desperate – does not mean there is no answer at all with today's assisted reproductive technology.
I. Can azoospermia patients undergo IVF: Direct answer
Whether a Chinese man with azoospermia can have his own biological child through IVF technology depends critically on the specific type of azoospermia and whether residual spermatogenic function exists in the testes. Azoospermia is not a single disease but is divided into two main categories, each with completely different treatment paths and outcomes.
Obstructive Azoospermia (OA) – Testicular spermatogenic function is normal, but the sperm ducts (epididymis, vas deferens, ejaculatory ducts) are blocked due to inflammation, injury, or congenital developmental abnormalities. These patients can obtain sperm through testicular sperm aspiration (TESA/PESA) or epididymal sperm aspiration, and then achieve fertilization using Intracytoplasmic Sperm Injection (ICSI, i.e., second-generation IVF). Clinical data show that for OA patients using aspirated sperm for ICSI, fertilization rates, good-quality embryo rates, and clinical pregnancy rates are not significantly different from those of men with normal semen parameters.
Non-Obstructive Azoospermia (NOA) – There is a disorder of spermatogenic function within the testes themselves, which may be caused by congenital genetic factors, endocrine abnormalities, post-infection damage, or environmental factors. These patients first need to undergo testicular biopsy or microdissection testicular sperm extraction (micro-TESE) to evaluate spermatogenic function. Micro-TESE uses a surgical microscope to locate focal areas of spermatogenesis, with an overall sperm retrieval rate of about 40%–60% (depending on the cause and degree of testicular atrophy). If sperm are successfully retrieved, ICSI can be performed; if not, donor sperm IVF or adoption should be considered.
Simple summary: Obstructive azoospermia → IVF possible (sperm aspiration + ICSI); Non-obstructive azoospermia → evaluate spermatogenic function first → some can do IVF (micro-TESE + ICSI), some need donor sperm. Therefore, the question "Can azoospermia patients undergo IVF?" must be answered based on a clear classification.
II. Classifying diagnosis and key examination indicators for azoospermia
From the clinical decision-making logic of a reproductive andrologist, when a patient presents with "azoospermia," we need to answer three questions in sequence: ① Is it truly azoospermia? ② Is it obstructive or non-obstructive? ③ Does the testis still have spermatogenic function? Each step relies on specific examinations.
2.1 Semen analysis – Basis of diagnosis
Diagnosing azoospermia requires that no sperm are found after microscopic examination of the centrifuged pellet from at least 3 semen samples. Centrifugation is performed at 3000 rpm for 15 minutes, and the sediment is thoroughly scanned under a microscope. A single negative test is insufficient for diagnosis, as factors like the ejaculation interval or incomplete sample collection can lead to false negatives. Mr. Zhang's three negative results confirm azoospermia.
2.2 Sex hormone profile – Core indicator for differentiating obstructive from non-obstructive
| Hormone | Obstructive Azoospermia (OA) | Non-Obstructive Azoospermia (NOA) | Clinical Significance |
|---|---|---|---|
| FSH (Follicle-Stimulating Hormone) | Normal or low | Significantly elevated | FSH is the most sensitive indicator of spermatogenic function. FSH > 7.6 IU/L suggests impaired spermatogenesis; > 12 IU/L often indicates severe spermatogenic failure. |
| LH (Luteinizing Hormone) | Normal | Normal or elevated | Elevated LH suggests impaired Leydig cell function, possibly related to chromosomal abnormalities. |
| Testosterone (T) | Normal | Normal or low | Very low testosterone indicates insufficient Leydig cell function, requiring consideration of endocrine therapy. |
| PRL (Prolactin) | Normal | Normal | Elevation requires ruling out endocrine diseases like pituitary adenoma. |
2.3 Chromosomal karyotype analysis and Y-chromosome microdeletion – Genetic etiology screening
These two tests are indispensable in the diagnosis of azoospermia and must be completed before any sperm retrieval procedure.
- Chromosomal karyotype analysis: Used to screen for Klinefelter syndrome (47,XXY) and other structural abnormalities. Klinefelter syndrome is the most common genetic cause of NOA, accounting for about 10%–15%.
- Y-chromosome microdeletion (AZF gene testing): Divided into AZFa, AZFb, and AZFc regions. Patients with AZFc deletions still have a 50%–70% chance of finding sperm via micro-TESE; those with complete AZFa or AZFb deletions have extremely low sperm retrieval rates, and donor sperm is usually recommended directly.
2.4 Testicular volume measurement and seminal plasma biochemistry
- Testicular volume: Normal adult male testicular volume is 15–25 ml. Volume less than 10 ml indicates significant spermatogenic impairment, and less than 6 ml indicates very poor spermatogenesis. However, volume is not an absolute criterion; a few small testes may still contain focal spermatogenesis.
- Seminal plasma biochemistry: Includes fructose (from seminal vesicles), α-glucosidase (from epididymis), and acid phosphatase (from prostate). Negative fructose suggests seminal vesicle agenesis or ejaculatory duct obstruction; significantly reduced α-glucosidase suggests epididymal obstruction. These indicators are valuable for locating the site of obstruction.
How the doctor sees it: In clinical practice, about 15% of azoospermia patients have a final diagnosis that differs from the initial impression after systematic evaluation. For example, some patients with high FSH may still have small foci of spermatogenesis on testicular biopsy; conversely, some patients with normal FSH may have complete loss of spermatogenic function due to Y-chromosome AZFb deletion. Therefore, we always emphasize comprehensive evaluation and avoiding single-indicator judgment. This is why azoospermia patients must complete the full set of tests in a reproductive andrology clinic before making decisions.
III. Complete process and timeline for azoospermia IVF
The IVF process for azoospermia patients is similar to conventional IVF but differs significantly in the male sperm retrieval step. Below, the complete pathway is illustrated using the most common examples: TESA+ICSI for Obstructive Azoospermia (OA) and micro-TESE+ICSI for Non-Obstructive Azoospermia (NOA).
3.1 Standard process (using OA as an example)
| Step | Content | Timeline |
|---|---|---|
| ① Male diagnosis & classification | Complete semen analysis, sex hormones, karyotype, Y-chromosome microdeletion, seminal plasma biochemistry, testicular volume measurement, and testicular biopsy if necessary. | 1–2 months |
| ② Female pre-IVF workup | AMH, FSH, LH, E2, antral follicle count, thyroid function, infectious disease screening, hysteroscopy (if needed). | Concurrent with male workup, about 1 month |
| ③ Determine sperm retrieval plan | OA: TESA or PESA; NOA: micro-TESE; if evaluation suggests extremely low success rate, discuss donor sperm plan in advance. | Determined before starting the cycle |
| ④ Female ovarian stimulation | Antagonist protocol or long protocol, monitoring follicle development via ultrasound and hormones. | About 10–14 days |
| ⑤ Synchronized sperm retrieval on egg retrieval day | On the day of female egg retrieval, male undergoes TESA/PESA or micro-TESE to obtain sperm; laboratory performs ICSI immediately. | 1 day |
| ⑥ Embryo culture & transfer | Observe fertilization, cleavage, blastocyst formation after ICSI; perform PGT if indicated; fresh or frozen embryo transfer. | 3–6 days post-egg retrieval (fresh) or 1–2 months later (frozen) |
| ⑦ Luteal support & follow-up | Use progesterone or HCG for luteal support after transfer; check serum HCG 12–14 days post-transfer. | Continues until 10–12 weeks of pregnancy |
3.2 Key timeline notes
- Testing phase: Male karyotype and Y-chromosome microdeletion tests take 15–20 business days for results; early scheduling is recommended. Semen analysis requires 3–5 days of abstinence; repeat tests should be at least 1 week apart.
- Ovarian stimulation cycle: The specific protocol depends on the female's age and ovarian reserve. Patients with AMH below 1.2 ng/ml may use PPOS or mild stimulation, which takes slightly longer.
- Sperm retrieval surgery: TESA/PESA are outpatient procedures; patients can be discharged after 1–2 hours of rest. Micro-TESE is performed in an operating room; rest for 1–2 days post-surgery is recommended.
- Embryo transfer: If PGT (third-generation IVF) is performed, waiting for blastocyst biopsy results adds 1–2 months for a frozen embryo transfer cycle.
From the start of testing to completing the transfer, the total cycle typically takes 2–4 months, depending on the protocol and individual circumstances.
IV. Differences in azoospermia IVF protocols across countries
When azoospermia patients choose IVF, differences in medical policies, technological availability, and legal frameworks across countries directly influence protocol selection. The main differences are listed objectively below for reference.
| Country/Region | Policy & Legal Environment | Technical Features | Donor Sperm Accessibility | Estimated Cost (CNY) |
|---|---|---|---|---|
| Mainland China | Requires ID, marriage certificate, and birth permit (three documents); sex selection prohibited; donor sperm requires waiting at approved sperm banks, 6–24 months. | Micro-TESE is available in provincial-level reproductive centers; ICSI is well-established; PGT limited to clear genetic indications. | Strictly regulated, donor sperm from official banks, anonymous between donor and recipient. | OA IVF: 30,000–50,000; NOA micro-TESE+ICSI: 50,000–80,000; Donor sperm IVF: 30,000–60,000 |
| United States | Well-established legal system for donor sperm, donor eggs, and surrogacy; sex selection allowed; commercial surrogacy legal in some states. | Micro-TESE widely available with experienced surgeons; PGT-A commonly used; high laboratory quality standards. | Wide selection of sperm banks with transparent information (height, education, blood type, family history), short waiting times. | OA IVF: $20,000–$30,000; NOA+micro-TESE: $30,000–$40,000; Donor sperm IVF: $20,000–$25,000 |
| Japan | Relatively conservative policies; donor sperm restricted to designated institutions; surrogacy prohibited; strict age limits (female usually ≤42). | Micro-TESE is at the international forefront with extensive experience in NOA; ICSI success rates similar to Europe/US. | Limited donor sperm sources, longer waiting times. | OA IVF: 40,000–60,000; Micro-TESE+ICSI: 70,000–100,000 |
| Thailand | Relatively relaxed policies for PGT; can screen for chromosomal number and structural abnormalities; donor sperm through approved agencies; commercial surrogacy not allowed (for locals). | Some centers have micro-TESE; well-established international patient service processes. | More donor sperm options than in China, shorter waiting times. | OA IVF: 50,000–80,000; Micro-TESE+ICSI: 80,000–120,000; Donor sperm IVF: 50,000–80,000 |
Note: Cost estimates are based on 2024 public information. Actual costs vary depending on individual protocols, medication dosage, number of cycles, etc. Before seeking treatment abroad, fully understand local medical regulations, language communication costs, and follow-up arrangements.
V. Most easily overlooked details in azoospermia IVF
In clinical work, we find that patients and even some non-specialist doctors often overlook the following key aspects, which can directly affect the final outcome.
- Chromosomal testing must be completed before sperm retrieval: Some patients rush into the IVF cycle and undergo sperm retrieval surgery before chromosome results are available. If the karyotype is 47,XXY (Klinefelter syndrome) or shows complete AZFa/AZFb deletion, the sperm retrieval success rate is extremely low, and early surgery may cause unnecessary trauma and expense.
- FSH is not the sole indicator for predicting sperm retrieval: Significantly elevated FSH (>15 IU/L) does indicate severe spermatogenic impairment, but about 20%–30% of patients can still have sperm found via micro-TESE. We have encountered patients with FSH as high as 22 IU/L and testicular volume of only 6 ml who successfully had sperm retrieved via micro-TESE and achieved pregnancy. Therefore, high FSH is not an absolute reason to give up trying.
- Testicular volume less than 6 ml is not an absolute contraindication: Small volume does not mean a complete absence of spermatogenic foci. Especially for patients with Klinefelter syndrome, although testicular volume is usually less than 6 ml, the success rate of micro-TESE is still 40%–50%.
- Patients with AZFc deletion need genetic counseling: If sperm are obtained via micro-TESE and ICSI is performed, male offspring will 100% carry the AZFc deletion and will face azoospermia in adulthood. This genetic risk must be communicated to the patient before the procedure.
- Seminal plasma biochemistry is crucial for locating obstruction: Some patients rely solely on imaging (e.g., vasography) to determine the obstruction site, but seminal plasma biochemistry can more accurately reflect epididymal and seminal vesicle function, avoiding unnecessary exploratory surgery.
Common misconception: Some patients believe "azoospermia means absolute infertility" or that "taking Chinese herbal medicine for a while will make the sperm come back." In reality, for obstructive azoospermia, medication cannot resolve mechanical obstruction; for non-obstructive azoospermia, spermatogenic damage is usually irreversible. Blindly waiting or trying unproven treatments may delay the optimal fertility window, especially as female age advances and ovarian function declines, further reducing IVF success rates.
VI. Treatment plans for special types of azoospermia
Below are several common special types of azoospermia encountered clinically, each with distinct evaluation focuses and fertility strategies.
6.1 Klinefelter syndrome (47,XXY)
Klinefelter syndrome is the most common genetic cause of male infertility, accounting for about 10%–15% of azoospermia patients. Typical features include small testicular volume (usually <6 ml), significantly elevated FSH, and low-normal testosterone. Micro-TESE is the currently recommended standard sperm retrieval method, with a sperm retrieval rate of about 40%–50%. When sperm are found and ICSI is performed, the clinical pregnancy rate is slightly lower than for OA patients but can still reach 30%–40% per transfer cycle. Some patients may undergo endocrine pre-treatment with letrozole or hCG before surgery to potentially improve sperm retrieval rates, though high-quality evidence is lacking.
6.2 Y-chromosome AZF deletion
| Deletion Type | Micro-TESE Success Rate | Genetic Risk to Offspring | Recommended Strategy |
|---|---|---|---|
| Complete AZFa deletion | < 5% | Male offspring carry the deletion | Proceed directly to donor sperm IVF |
| Complete AZFb deletion | < 10% | Male offspring carry the deletion | Donor sperm recommended; micro-TESE can be attempted but with full disclosure of very low success rate |
| AZFc deletion | 50%–70% | Male offspring 100% carry AZFc deletion, azoospermia in adulthood | Micro-TESE + ICSI can be attempted; genetic counseling is mandatory |
6.3 Azoospermia after cryptorchidism surgery
In patients who underwent orchiopexy for undescended testes (cryptorchidism) in childhood, some still develop azoospermia in adulthood. Sperm retrieval rates are closely related to the age at surgery: those operated on before age 2 generally have normal spermatogenic function in adulthood; those operated on after age 6 have a significantly increased risk of azoospermia. For patients with confirmed azoospermia after cryptorchidism surgery, micro-TESE remains the first choice, with a success rate of about 30%–50%, depending on testicular development.
6.4 Azoospermia after mumps orchitis
Infection with the mumps virus after puberty causing orchitis leads to testicular atrophy in about 30%–50% of cases. If both testes are affected, it can result in permanent azoospermia. Spermatogenic function is usually not completely lost in these patients, and the micro-TESE success rate is about 40%–60%. FSH level and testicular volume are the main predictors of sperm retrieval success.
6.5 Azoospermia after chemotherapy
Chemotherapeutic agents, especially alkylating agents like cyclophosphamide and busulfan, cause significant damage to spermatogenic function. The potential for recovery of spermatogenesis in post-chemotherapy azoospermia depends on the chemotherapy regimen, dosage, and patient age. Routine sperm cryopreservation before chemotherapy is recommended; if not done and azoospermia is confirmed post-chemotherapy, micro-TESE can be attempted, with a success rate of about 20%–40%, closely related to the type of chemotherapy drug.
Doctor's advice: For azoospermia patients considering IVF, it is recommended to proceed steadily with the following steps:
- Visit a reproductive andrology specialist at a正规 hospital's reproductive medicine center. Complete systematic testing (semen analysis, sex hormones, karyotype, Y-chromosome microdeletion, seminal plasma biochemistry, testicular ultrasound) to determine the type of azoospermia.
- Based on the results, discuss the sperm retrieval plan with your doctor (TESA/PESA / micro-TESE / donor sperm). Do not blindly insist on "using your own sperm," but also do not give up trying easily.
- Simultaneously, the female partner should complete a fertility assessment (AMH, ovarian reserve, uterine conditions) to develop an overall treatment timeline. Female age is one of the most critical factors affecting success rates; do not delay excessively due to the male evaluation.
- If a donor sperm plan is involved, learn about the sperm bank procedures and waiting times in advance, and prepare mentally.
- Maintain realistic expectations. The success rate of IVF for azoospermia is influenced by multiple factors, including female age, embryo quality, and uterine environment. There is no "guaranteed success" plan; be wary of any institution promising a specific success rate.
After completing systematic testing, Mr. Zhang was diagnosed with obstructive azoospermia (epididymal obstruction), FSH 5.2 IU/L, karyotype 46,XY, no Y-chromosome deletion. We arranged a TESA+ICSI cycle for him. His wife had 14 eggs retrieved, 8 usable embryos were formed after ICSI, and a day-5 blastocyst transfer resulted in a successful pregnancy. Azoospermia is not the end; the key is to follow the correct diagnostic and treatment path.
Risk reminder: The content of this article is based on general knowledge of assisted reproductive medicine and does not constitute individualized medical advice. The specific treatment plan for azoospermia patients must be formulated by a reproductive specialist based on complete test results. The success rates mentioned in the article are ranges reported in the literature and do not represent individual outcomes. Do not choose a plan on your own without a doctor's evaluation.
Comments (0)